Recent advance of KRAS-G12C inhibitors for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• The RAS gene family, particularly KRAS, is central to cellular signaling and cancer development.
• KRAS mutations, especially G12C, are prevalent in human cancers, driving uncontrolled proliferation and metastasis.
• Targeting KRAS oncoproteins is a key strategy in cancer therapy.

Purpose of the Study:

• To provide an overview of current medicinal chemistry approaches for developing KRAS G12C inhibitors.
• To highlight innovations in KRAS G12C inhibitor design.
• To offer frameworks for future therapeutic development against KRAS G12C.

Main Methods:

• Review of contemporary medicinal chemistry literature.
• Analysis of drug development strategies for KRAS G12C inhibitors.
• Synthesis of insights from existing research and clinical data.

Main Results:

• The development of KRAS G12C inhibitors, such as Sotorasib (AMG510), has shown promise.
• Emerging resistance mechanisms necessitate ongoing medicinal chemistry efforts.
• Numerous KRAS G12C inhibitors are in various stages of clinical development.

Conclusions:

• Medicinal chemistry plays a vital role in advancing KRAS G12C targeted therapies.
• Understanding resistance mechanisms is key to designing next-generation inhibitors.
• This review provides valuable insights for developing novel therapeutics against KRAS G12C-driven cancers.